Active Biotech AB (publ) (STO:ACTI)

Market Cap	127.06M +17.6%
Revenue (ttm)	n/a
Net Income	-38.50M
EPS	-0.04
Shares Out	2.64B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,716,480
Average Volume	21,906,402
Open	0.0474
Previous Close	0.0480
Day's Range	0.0470 - 0.0498
52-Week Range	0.0370 - 0.3400
Beta	1.39
RSI	57.24
Earnings Date	Feb 12, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvir...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACTI